Skip to main content
Premium Trial:

Request an Annual Quote

Strand, BioHealth Partner to Expand Sequencing-based Diagnostic Services to US

NEW YORK (GenomeWeb News) – Strand Genomics and BioHealth Innovation today announced a strategic partnership to expand the Strand Centers for Genomics and Personalized Medicine into the US.

As part of the deal, BHI will connect Strand with "key" market channels, providing patients and healthcare providers with access to genomic services. Based in Rockville, Md., BHI describes itself as an "innovation intermediary that translates market-relevant research into commercial success by connecting management, funding, and markets."

Financial and other terms of the deal were not disclosed.

Strand Genomics, a wholly owned subsidiary of Strand Life Sciences in Bangalore, India, provides bioinformatics products and services. The Strand Centers for Genomics and Personalized Medicine are clinical labs for sequencing-based diagnostic services.

In December, Strand Life Sciences announced a collaboration with El Camino Hospital in Mountain View, Calif., to create the Strand Center for Genomics and Personalized Medicine at the Genomic Medicine Institute of the El Camino Hospital.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.